The Main Reason Why Azastene Rates Will Be Big

0 mmol/L for men and VE-821 in vitro drug treatment; (iv) body mass index (BMI) ��30 kg/m2; (v) hypertension with blood pressure ��130/85 mmHg or antihypertensive treatment. Study measurements Demographic, anthropometric and laboratory data as well as information about lifestyle habits were collected on all participants at the time of diagnosis and at each follow-up visit. Blood was collected by venepuncture after an overnight fast of at least 10 h at all follow-up examinations. The Central Laboratory of Medical Faculty, University of P��cs measured all serum chemistry levels in fresh samples with commercially available reagents. The glomerular filtration rate (eGFR; mL/min/1.73 m2) was estimated with the Chronic Kidney Disease Epidemiology Collaboration equation [13]. BMI was calculated as weight in kilograms divided by the square of the height in metres. Definition of progression of IgAN The primary renal outcome was the doubling of serum creatinine, secondary renal outcomes were the decrease of eGFR to ��60 mL/min/1.73 m2, or to ��30 mL/min/1.73 m2 or reaching ESRD (defined as the composite of a serum creatinine ��500 ?mol/L or the initiation of dialysis treatment or transplantation). Statistical analysis Data analysis was performed using the SPSS software program version 13.0 (SPSS Inc., Chicago, IL, USA). Continuous variables with normal distribution were expressed as mean �� standard deviation and were compared by using Pictilisib price Azastene Student's t-tests. Variables with non-normal distribution were compared by the Mann�CWhitney U-test, and categorical variables were expressed as percentage and compared by the ��2 test. The mean renal survival time until the selected end points was calculated using the Kaplan�CMeier method. Differences between the calculated mean renal survival times were compared using the log-rank test. The effect of confounders was assessed by Cox regression analysis. Confounders were determined a priori based on theoretical considerations and by examining baseline covariate associations with metabolic syndrome and with the renal end points [14]. Multivariate models were constructed with sequential adjustments for age and gender as well as for age, gender, uric acid, eGFR, smoking and angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker (ACEis/ARB). A value of P